References and Trials

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/224

encourage image

There's no tags or description

Looks like no tags are added yet.

225 Terms

1
New cards

Who established the four-group classification of protein therapeutics, and when?

Leader et al. (2008): proteins classified by enzymatic/regulatory, targeting, vaccine, or diagnostic action.

2
New cards

Which review reported mAbs as 53.5% of 2018–2022 biopharmaceutical approvals?

Walsh & Walsh (2022).

3
New cards

What did Kaplon et al. (2020) report about mAb targets?

Just 10 targets accounted for about 42% of historically approved mAbs.

4
New cards

What was Uhlén et al. (2015) known for in the notes?

Mapping the human tissue proteome: ~3,000 secreted-protein and ~5,500 membrane-protein genes.

5
New cards

What clinical issue did Roda et al. (2016) examine?

Primary non-response and subsequent loss of response during anti-TNF therapy.

6
New cards

What did Vu & Claret (2012) review?

Primary and acquired resistance to HER2-directed trastuzumab; need for predictive biomarkers.

7
New cards

What did O’Connell et al. (2002) compare?

Multivalent versus monovalent phage display using scFvs; selection/expression performance.

8
New cards

What did Gourgari et al. (2017) review?

Engineered insulin analogues classified by altered onset and duration of action.

9
New cards

Who invented hybridoma technology, and in what year?

Köhler and Milstein, 1975; fusion of antigen-specific B cells with immortal myeloma cells.

10
New cards

Who shared the 1984 Nobel Prize for monoclonal-antibody-related work?

Köhler, Milstein and Niels Jerne.

11
New cards

What was the first FDA-approved therapeutic monoclonal antibody and year?

Murine muromonab-CD3 (OKT3), 1986.

12
New cards

Which first recombinant human insulin was approved in 1982?

Humulin: recombinant human insulin.

13
New cards

Which year was trastuzumab approved, according to the lecture?

1998.

14
New cards

Which year was adalimumab approved, according to the lecture?

2002; a fully human anti-TNF mAb.

15
New cards

What did Hudis (2007) describe?

Trastuzumab mechanisms, HER2 signalling and cardiotoxicity.

16
New cards

What was the key message of Carter & Lazar (2018)?

Antibody target difficulty: accessible “low-hanging” targets versus challenging “high-hanging” ones.

17
New cards

What did Chan, Martyn & Carter (2025) review?

50 years of antibody development, newer formats, subcutaneous delivery and AI-assisted design.

18
New cards

Which 2011 paper updated the hallmarks of cancer?

Hanahan & Weinberg (2011): emerging hallmarks plus enabling characteristics.

19
New cards

What did Sharma & Allison (2015) emphasize?

T-cell activation/checkpoint biology and rationale for treating hot versus cold tumours.

20
New cards

What did Ribas & Wolchok (2018) examine?

Checkpoint therapy mechanisms and resistance involving JAK1/2 or β2-microglobulin.

21
New cards

What discovery earned Karikó and Weissman the 2023 Nobel Prize?

Nucleoside-base modifications enabling effective mRNA vaccine development.

22
New cards

Which authors reviewed blinatumomab pharmacology in 2019?

Burt, Warcel and Fielding: half-life, continuous infusion, CRS and neurotoxicity.

23
New cards

What did Kitazawa et al. (2012) demonstrate?

Preclinical bispecific FIXa–FX bridging that mimics FVIIIa cofactor function.

24
New cards

What did Guo et al. (2021) explain?

Amivantamab dual EGFR/MET binding, Fc engineering and activity in TKI-resistant NSCLC.

25
New cards

What did Kalra & Sahay (2020) review?

Oral semaglutide as a GLP-1 receptor agonist for type 2 diabetes.

26
New cards

What did Drucker (2025) review?

GLP-1-based therapies for diabetes, obesity and wider indications.

27
New cards

What did Wilson & Castle (2020) review?

Recent advances in insulin therapy and delivery.

28
New cards

What did Bain & Brazil (2003) describe?

Adalimumab, the fully human anti-TNF therapeutic antibody.

29
New cards

What did Johnson & Jiang (2023) review?

Infection, autoantibodies and the development of autoimmunity.

30
New cards

What did Monteleone et al. (2023) review?

Shared and distinct pathogenic and clinical features of inflammatory diseases.

31
New cards

Which study established a survival benefit from adding trastuzumab to first-line chemotherapy?

Slamon et al.: metastatic HER2-positive breast cancer.

32
New cards

What was time to progression in the pivotal Slamon trastuzumab study?

7.4 months with trastuzumab + chemotherapy versus 4.6 months with chemotherapy alone.

33
New cards

What was overall survival in the pivotal Slamon trastuzumab study?

25.1 months with trastuzumab + chemotherapy versus 20.3 months with chemotherapy alone.

34
New cards

Which three adjuvant trastuzumab trials are cited?

HERA, BCIRG 006 and NCCTG N-9831.

35
New cards

What recurrence-risk reductions are attributed to adjuvant trastuzumab in the notes?

Approximately 36–51%, depending on trial and analysis.

36
New cards

What death-risk reductions are attributed to adjuvant trastuzumab in the notes?

Approximately 34–41%, depending on trial and analysis.

37
New cards

What toxicity strongly limits trastuzumab with anthracyclines?

Cardiac dysfunction/heart failure; HER2 signalling supports cardiomyocyte survival and repair.

38
New cards

What heart-failure incidences with trastuzumab combinations are quoted?

27% with anthracyclines versus 13% with paclitaxel; context-specific historical estimates.

39
New cards

What did Hodi et al. (2010) demonstrate for ipilimumab?

Phase III overall survival benefit in metastatic melanoma, with immune-related toxicities.

40
New cards

What immune checkpoint does ipilimumab block?

CTLA-4; it permits stronger CD28-mediated T-cell priming.

41
New cards

What approximate objective response rate is quoted for ipilimumab monotherapy?

~15% in metastatic melanoma; responses could be durable.

42
New cards

What long-term survival observation is quoted for ipilimumab?

~20% survived more than 4 years in the cited historical context.

43
New cards

What did KEYNOTE-006 compare?

Pembrolizumab versus ipilimumab in advanced melanoma.

44
New cards

What did Robert et al. (2015) report in KEYNOTE-006?

Pembrolizumab improved progression-free and overall survival versus ipilimumab.

45
New cards

What approximate response rate is quoted for nivolumab + ipilimumab in melanoma?

~60%; combination has higher toxicity than single-agent PD-1 blockade.

46
New cards

What 3-year OS figures are quoted for combination versus nivolumab alone?

58% with nivolumab + ipilimumab versus 52% with nivolumab alone.

47
New cards

Why can MSI-high / mismatch-repair-deficient tumours respond to PD-1 blockade?

High mutation/neoantigen burden can increase T-cell recognition.

48
New cards

What is the quoted ORR for checkpoint blockade in Hodgkin lymphoma?

87% in the specific cited context; not a universal rate for all studies.

49
New cards

What is the quoted ORR for checkpoint blockade in desmoplastic melanoma?

70% in the specific cited context.

50
New cards

What is the quoted ORR for checkpoint blockade in MSI-high cancer?

53% in the specific cited context.

51
New cards

What response rate is quoted for PD-L1-negative patients on nivolumab?

17%; illustrates that PD-L1 negativity does not guarantee no response.

52
New cards

What exploratory biomarker increased after presurgical ipilimumab in bladder cancer?

ICOS expression on CD4+ T cells in tumour and blood.

53
New cards

Which chromosomal change contributes to PD-L1 upregulation in classical Hodgkin lymphoma?

Chromosome 9p24.1 amplification affecting PD-L1/PD-L2 and JAK2.

54
New cards

Which approved melanoma combination blocks PD-1 and LAG-3?

Nivolumab + relatlimab (Opdualag).

55
New cards

What did the KATHERINE trial compare?

Adjuvant T-DM1 versus trastuzumab after residual invasive HER2+ breast cancer post-neoadjuvant therapy.

56
New cards

What were the KATHERINE 3-year invasive disease-free survival rates?

88.3% for T-DM1 versus 77.0% for trastuzumab.

57
New cards

What was the KATHERINE invasive recurrence/death hazard ratio?

HR 0.50 (95% CI 0.39–0.64; p < 0.001).

58
New cards

What does HR 0.50 mean in KATHERINE?

Approximately 50% lower hazard of invasive recurrence or death, not 50 percentage points higher iDFS.

59
New cards

What KATHERINE toxicity caused discontinuation in 4.2%?

Thrombocytopenia (decreased platelet count).

60
New cards

What KATHERINE toxicity caused discontinuation in 1.5%?

Peripheral sensory neuropathy.

61
New cards

What did DESTINY-Breast04 compare?

Trastuzumab deruxtecan (T-DXd) versus physician’s choice of chemotherapy in HER2-low metastatic breast cancer.

62
New cards

How was HER2-low defined in DESTINY-Breast04?

IHC 1+ or IHC 2+ with negative ISH.

63
New cards

What were DESTINY-Breast04 median PFS values in the HR-positive cohort?

10.1 months with T-DXd versus 5.4 months with chemotherapy.

64
New cards

What was the DESTINY-Breast04 PFS hazard ratio?

HR 0.51; approximately 49% lower progression/death hazard in the compared groups.

65
New cards

What were DESTINY-Breast04 median OS values in the HR-positive cohort?

23.9 months with T-DXd versus 17.5 months with chemotherapy.

66
New cards

What was the DESTINY-Breast04 OS hazard ratio?

HR 0.64; approximately 36% lower death hazard.

67
New cards

What serious toxicity is associated with T-DXd?

Interstitial lung disease/pneumonitis, potentially fatal.

68
New cards

What ILD incidence and fatal incidence are quoted for DESTINY-Breast04?

12.1% ILD and 0.8% grade 5 fatal events in the trial report cited.

69
New cards

What did the phase III TOWER trial compare?

Blinatumomab versus salvage chemotherapy in adult relapsed/refractory B-cell ALL.

70
New cards

What were median OS results in TOWER?

7.7 months with blinatumomab versus 4.0 months with chemotherapy.

71
New cards

What was the TOWER overall survival HR and p-value?

HR 0.71 (95% CI 0.55–0.93), p = 0.01.

72
New cards

What CR rates with full haematologic recovery were reported in TOWER?

34% with blinatumomab versus 16% with chemotherapy within 12 weeks.

73
New cards

What did Kantarjian et al. (2017) publish?

The TOWER phase III blinatumomab versus chemotherapy results.

74
New cards

What did BLAST investigate?

Blinatumomab for B-ALL in morphological remission but with measurable residual disease.

75
New cards

What proportion became MRD-negative after one BLAST cycle?

78% of evaluable patients in the stated analysis.

76
New cards

What median overall survival is quoted for BLAST follow-up?

36.5 months; a follow-up estimate, not evidence of a randomized comparison.

77
New cards

What does MRD >10^-3 mean?

More than roughly 1 detectable malignant cell per 1,000 measured cells by the specified assay.

78
New cards

Why is blinatumomab step-dosed?

To reduce early cytokine release syndrome as CD3-engaged T cells activate.

79
New cards

What step-up blinatumomab doses are quoted?

9 μg/day in week 1, then 28 μg/day; schedule depends on indication and label.

80
New cards

What did HAVEN 1 test?

Emicizumab prophylaxis for haemophilia A with FVIII inhibitors.

81
New cards

What bleeding reduction is attributed to HAVEN 1?

87% lower treated bleeding rate with emicizumab prophylaxis versus no prophylaxis.

82
New cards

Who reported HAVEN 1 in 2017?

Oldenburg et al.

83
New cards

What did CHRYSALIS study?

Amivantamab in platinum-pretreated EGFR exon 20 insertion NSCLC.

84
New cards

What objective response rate was reported in CHRYSALIS?

40% in the specified EGFR exon 20 insertion cohort.

85
New cards

What median duration of response was reported in CHRYSALIS?

11.1 months.

86
New cards

What did phase III PAPILLON test?

First-line amivantamab plus chemotherapy versus chemotherapy in EGFR exon 20 insertion NSCLC.

87
New cards

What was PAPILLON’s key conclusion in the notes?

Amivantamab + chemotherapy significantly improved progression-free survival.

88
New cards

Who published PAPILLON according to the notes?

Zhou et al. (2023).

89
New cards

What did the EDITION 1 and 2 insulin trials compare?

Glargine U-300 versus glargine U-100.

90
New cards

What did EDITION 1/2 find for HbA1c lowering?

Similar HbA1c reduction with U-300 and U-100.

91
New cards

What safety advantage did glargine U-300 show in EDITION?

Less nocturnal hypoglycaemia in the cited comparisons.

92
New cards

What did SWITCH 1 and SWITCH 2 compare?

Insulin degludec versus glargine U-100.

93
New cards

What did SWITCH 1/2 show?

Less symptomatic, especially nocturnal, hypoglycaemia with degludec.

94
New cards

Which ultra-rapid lispro trials are cited?

PRONTO-T1D and PRONTO-T2D.

95
New cards

What outcome is emphasised in PRONTO trials?

Improved early post-meal glucose excursions versus conventional lispro in cited analyses.

96
New cards

What initial blood appearance times were quoted for Fiasp and standard aspart?

4 versus 9 minutes, respectively, in the lecture comparison.

97
New cards

What does the PIONEER clinical programme study?

Oral semaglutide in type 2 diabetes.

98
New cards

What did PIONEER 4 compare?

Oral semaglutide with liraglutide (and placebo in the study).

99
New cards

What weight-loss values are quoted for PIONEER 4?

4.4 kg with oral semaglutide versus 3.1 kg with liraglutide.

100
New cards

What was the primary cardiovascular design purpose of PIONEER 6?

A cardiovascular outcomes safety/noninferiority assessment of oral semaglutide.